1b0cc94a3b
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
- Source: inbox/queue/2026-04-21-apotex-fda-tentative-approval-generic-semaglutide.md - Domain: health - Claims: 0, Entities: 2 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
27 lines
No EOL
1.1 KiB
Markdown
27 lines
No EOL
1.1 KiB
Markdown
---
|
|
type: entity
|
|
entity_type: company
|
|
name: Apotex Inc.
|
|
domain: health
|
|
status: active
|
|
founded: null
|
|
headquarters: Canada
|
|
website: https://www.apotex.com
|
|
tags: [generic-pharmaceuticals, semaglutide, GLP-1, biosimilar]
|
|
---
|
|
|
|
# Apotex Inc.
|
|
|
|
Canadian generic pharmaceutical manufacturer.
|
|
|
|
## Overview
|
|
|
|
Apotex is a generic pharmaceutical company that received the first US FDA tentative approval for generic semaglutide injection in partnership with Orbicular Pharmaceutical Technologies.
|
|
|
|
## Timeline
|
|
|
|
- **2026-04-10** — Received first US FDA tentative approval for generic semaglutide injection (ANDA) in partnership with Orbicular Pharmaceutical Technologies. As first ANDA filer, would receive 180 days of market exclusivity upon commercial launch. Tentative approval confirms application meets FDA standards but does not permit marketing due to Novo Nordisk patent barriers extending to December 5, 2031.
|
|
|
|
## Strategic Position
|
|
|
|
First-mover position in US generic semaglutide market with regulatory approval complete but commercial launch blocked by patent thicket. Realistic market entry: 2031-2033. |